This article is more than 5 years old. Information may no longer be current.

EyeGate reports $4.1 million quarterly loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported a net loss of $4.1 million in the third quarter of 2017 compared with a net loss of $3.4 million in the same time period of 2016.

Revenues were down from $0.274 million in 2016’s third quarter to $0.075 million in the third quarter of 2017, according to a press release.

Research and development costs rose to $3.2 million in the quarter from $2.5 million in 2016’s third quarter, while general and administrative costs were down to $1 million from $1.2 million.

The company reported cash and cash equivalents of $9.2 million as of Sept. 30.